[{"id":"cf834b01-5b9b-4c32-bb23-b221bf405680","acronym":"","url":"https://clinicaltrials.gov/study/NCT02653976","created_at":"2021-01-18T12:55:59.721Z","updated_at":"2024-07-02T16:35:22.114Z","phase":"Phase 2","brief_title":"A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)","source_id_and_acronym":"NCT02653976","lead_sponsor":"Solasia Pharma K.K.","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zinapar (darinaparsin)"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 03/25/2016","start_date":" 03/25/2016","primary_txt":" Primary completion: 10/11/2020","primary_completion_date":" 10/11/2020","study_txt":" Completion: 06/17/2021","study_completion_date":" 06/17/2021","last_update_posted":"2024-01-26"}]